📰 Adcendo News
Adcendo News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adcendo. Real-time updates on events, politics, business and more.
April 4, 2024
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of...
May 30, 2023
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
April 4, 2023
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
April 4, 2023
Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP - News - PharmaTimes
January 5, 2023
Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in
May 3, 2022
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
April 11, 2022
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
December 1, 2021
/PRNewswire/ -- Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers,...
December 1, 2021
- Building the team with experienced biotech experts and renowned leaders in the ADC field - Underscores company's commitment to progressing lead program on novel ADC target uPARAP COPENHAGEN
April 29, 2021
Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was in...